Content area

|
|

Anti-interleukin 17 er en ny behandlingsmulighed for patienter med psoriasisgigt

Forfatter(e)
Frederik Heiberg Brix1, Camilla Møller1 & Bent Deleuran1, 2
1) Biomedicin, Health, Aarhus Universitet 2) Reumatologisk Afdeling, Aarhus Universitetshospital

Ugeskr Læger 2019;181:V09180610
Reference: 
Ugeskr Læger 2019;181:V09180610

Frederik Heiberg Brix, Camilla Møller & Bent Deleuran:

Anti-interleukin 17 is a new possible treatment of patients with psoriatic arthritis

Ugeskr Læger 2019;181:V09180610

Psoriatic arthritis (PsA) is a chronic inflammatory disease associated with comorbidity and decreased quality of life. The current treatment of PsA is non-steroid anti-inflammatory drugs or in more severe cases disease modifying antirheumatic drugs such as methotrexate or leflunomide, but these agents are often inadequately effective. Biologic tumour necrosis factor (TNF)-inhibitors are effective in the treatment of PsA. However, many patients lose efficacy or have an insufficient response to TNF-inhibitors. Biologic agents targeting interleukin-17A have shown encouraging clinical results.

Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Jens Skøt Hindrup | 18/04
1 Kommentar
af Debatred. | 15/04
1 Kommentar
af Martin Bonde Petersen | 15/04
1 Kommentar
af Anne Lisbeth Hoffmann | 15/04
4 kommentarer
af Jørgen Lous | 13/04
9 kommentarer
af Karin Marlen Moldrup | 13/04
3 kommentarer
af Merete Stampe Mølberg | 13/04
7 kommentarer